The Anti-Asthmatics And COPD Drugs by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Anti-Asthmatics And COPD Drugs Market:
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report
According to The Business Research Company’s Anti-Asthmatics And COPD Drugs, The anti-asthmatics and copd drugs market size has grown strongly in recent years. It will grow from $76.16 billion in 2023 to $81.41 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, rise in healthcare expenditure.
The anti-asthmatics and copd drugs market size is expected to see strong growth in the next few years. It will grow to $104.1 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and copd drugs to treat covid-19 patients, increasing consumption of fats . Major trends in the forecast period include developing probiotic drugs for asthma to offer a full range of available treatments, developing anti-il-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustain their position among intense competition in the market, invest more in developing bioelectric medicines to improve asthma care, focus on increasing the number of collaborations to expand their business portfolio, explore opportunities in personalized medicine to counter the intense competition and provide customized treatment to individuals, invest in aerosol respiratory drugs for better efficacy, investing in biomarkers to produce more effective drugs in a smaller time frame, focus efforts on investing in generic drugs to counter the intense competition, developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics..
Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market. Even though there is a decreasing trend in smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence. For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria by 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high-income countries including the USA and Europe. According to WHO, in developed countries, more than 35% of total energy requirement is derived from fats when compared to <20% in low-income countries, and less than 25% in lower-middle-income countries.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp
The anti-asthmatics and copd drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Major companies operating in the anti-asthmatics and COPD drugs market are innovating new products such as dose combination (FDC) drug, Indacaterol plus Mometasone to increase their profitability in the market. Indacaterol plus Mometasone, delivered via the Breezhaler device, is a once-daily fixed-dose combination (FDC) medication designed for the ongoing management of asthma in patients. For instance, in June 2022 Glenmark Pharmaceuticals, a US-based pharmaceutical company launched a novel-fixed dose combination (FDC) drug, Indacaterol plus Mometasone, for patients suffering from uncontrollable asthma in India. The medication, marketed as Indamet, is offered in three variations, all containing a consistent dose of 150 mcg of Indacaterol and variable doses of Mometasone, which come in 80 mcg, 160 mcg, and 320 mcg strengths.
The anti-asthmatics and copd drugs market report table of contents includes:
1. Executive Summary
2.Anti-Asthmatics And COPD Drugs Market Characteristics
3.Anti-Asthmatics And COPD Drugs Market Trends And Strategies
4.Anti-Asthmatics And COPD Drugs Market analysis
5.Anti-Asthmatics And COPD Drugs Market Size And Growth
6.Anti-Asthmatics And COPD Drugs Segmentation
7. Anti-Asthmatics And COPD DrugsRegional And Country Analysis
.
.
.
27.Anti-Asthmatics And COPD Drugs Competitive Landscape And Company Profiles
28.Anti-Asthmatics And COPD Drugs Key Mergers And Acquisitions
29.Anti-Asthmatics And COPD Drugs Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- GlaxoSmithKline PLC
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Novartis AG
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
